Sogroya 5 mg/ 1.5 ml

Sogroya 5 mg/ 1.5 ml is a medicine authorised by Swissmedic under authorisation number 69063. The authorisation holder is Novo Nordisk Pharma AG. The medicinal product code is Biotechnological medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 26 April 2024 and the authorisation is limited until 25 April 2029. ATC code H01AC07 places the medicine in the group Pituitary and hypothalamic hormones and analogues.

  • Dispensing category A
  • Authorisation number 69063
  • ATC H01AC07
  • Biotechnological medicines
Authorisation data
Authorisation number69063
NameSogroya 5 mg/ 1.5 ml
Full nameSogroya 5 mg/ 1.5 ml, Injektionslösung im Fertigpen
Authorisation holderNovo Nordisk Pharma AG
Medicinal product codeBiotechnological medicines
Dispensing categoryA · Prescription, not repeatable
ATC codeH01AC07
First authorisation26 April 2024
Authorisation validity25 April 2029
Strengths
No.NameDispensing categoryAuthorisation date
1Sogroya 5 mg/ 1.5 ml, Injektionslösung im FertigpenA26 April 2024
2Sogroya 10 mg/ 1.5 ml, Injektionslösung im FertigpenA26 April 2024
3Sogroya 15 mg/ 1.5 ml, Injektionslösung im FertigpenA26 April 2024

Scroll the table sideways

Pack sizes
Pack codeQuantityUnitATCIT codeDispensing category
11.5mlH01AC0707.03.1.A
21.5mlH01AC0707.03.1.A
31.5mlH01AC0707.03.1.A

Scroll the table sideways

Other medicines from this authorisation holder

Frequently asked questions

Is Sogroya 5 mg/ 1.5 ml authorised in Switzerland?

Yes. Sogroya 5 mg/ 1.5 ml is authorised by Swissmedic under authorisation number 69063, data as of 01 September 2026. The authorisation is limited until 25 April 2029.

Which dispensing category does Sogroya 5 mg/ 1.5 ml have?

Sogroya 5 mg/ 1.5 ml is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.

Who is the authorisation holder of Sogroya 5 mg/ 1.5 ml?

The authorisation holder is Novo Nordisk Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.

Sources

Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.

Authorisation in Switzerland?

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissmedicinesdirectory.com